Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Targeted CMV prophylaxis with valganciclovir viable

    • 10 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Targeted CMV prophylaxis with valganciclovir viable. Pharmacoecon. Outcomes News 314, 7 (2001). https://doi.org/10.1007/BF03280347

    Download citation

    Keywords

    • Valganciclovir
    • Oral Valganciclovir
    • Total Lifetime Cost
    • Adjusted Life Expectancy
    • Minor Adverse Reaction